Cline Darren S 4

What Happened

• Darren S. Cline, a director of Pliant Therapeutics, was granted a derivative award for 70,000 shares on June 11, 2026. The filing reports an acquisition price of $0.00 (code A — grant/award).
• This was a non-cash equity award (derivative interest), not an open-market purchase or sale, and therefore is primarily a form of compensation rather than an immediate bullish or bearish trading signal.

Key Details

• Transaction date and price: Grant on 2026-06-11; reported acquisition price $0.00.
• Shares involved: 70,000 shares as a derivative award (option/award); filing does not disclose total shares owned after the grant.
• Vesting: 25% vests Oct 1, 2026; 25% vests Jan 1, 2027; 25% vests Apr 1, 2027; remaining 25% vests on the earlier of (i) the one-year anniversary of the 6/11/2026 grant or (ii) the next annual meeting, subject to continued service as a director.
• Filing timeliness: Form 4 filed 2026-06-12 for a 2026-06-11 transaction — appears timely (filed one day after the grant).
• Filing notes: Recorded as a derivative grant (transaction code A). No 10b5-1 plan, tax-withholding, or late-filing flags are indicated in the provided data.

Context

• This award is typical director compensation structure (time-based vesting). It is a grant of equity-linked rights that vest over time, not an immediate exercise or sale of shares.
• For retail investors, grants signal alignment of director compensation with company performance and retention; they do not directly indicate trading intent or immediate share dilution until vested/exercised.